Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
140 hedge funds and large institutions have $299M invested in Catalyst Pharmaceutical in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 47 reducing their positions, and 15 closing their positions.
654% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $134K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
18% more capital invested
Capital invested by funds: $254M → $299M (+$45.2M)
7% more funds holding
Funds holding: 131 → 140 (+9)
1.18% less ownership
Funds ownership: 63.76% → 62.58% (-1.2%)
15% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 47
Top Buyers
| 1 |
NM
Newtyn Management
New York
|
+$4.49M |
| 2 |
Man Group
London,
United Kingdom
|
+$4.23M |
| 3 |
AC
Armistice Capital
New York
|
+$3.59M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.28M |
| 5 |
RA
Royce & Associates
New York
|
+$2.99M |
Top Sellers
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$5.51M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.93M |
| 3 |
BlackRock
New York
|
-$3.73M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.49M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Wolverine Trading
Chicago,
Illinois
| – | -$117K | -30,126 | Closed |
|
152
SG Americas Securities
New York
| – | -$78K | -20,148 | Closed |
|
|
BCM
153
Bayesian Capital Management
Brooklyn,
New York
| – | -$46K | -12,003 | Closed |
|
154
Walleye Capital
New York
| – | -$46K | -12,000 | Closed |
|
155
UBS Group
Zurich,
Switzerland
| – | -$9K | -2,275 | Closed |
|
CPRX Hedge Fund Activity: Q2 2020 in Review
140 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2020, worth a combined $299M — up 18% from $254M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CPRX positions and 15 closed out — a net gain of 9 holders — while 40 added to existing stakes and 47 trimmed.
The largest buyer was Newtyn Management, opening a new position worth an estimated $4.49M. The largest seller was Mangrove Partners, cutting an estimated $5.51M.
- 140 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2020, up from 131 in Q1 2020.
- Funds reported $299M of Catalyst Pharmaceutical stock for Q2 2020, up 18% quarter-over-quarter.
- 24 funds opened new Catalyst Pharmaceutical positions in Q2 2020 and 15 closed out, a net change of +9 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2020 was Newtyn Management, an estimated $4.49M added.
- The largest Catalyst Pharmaceutical seller in Q2 2020 was Mangrove Partners, an estimated $5.51M sold.
Based on aggregated 13F filings for Q2 2020.